SP-2509 has been investigated for use as an anti-cancer drug against cancers with high LSD1 expression and poor prognosis, including acute myeloid leukemia (36), Ewing sarcoma (43), and advanced prostate cancer (37). Here, KDM1A is linked to prostate cancer.